Texas-based Talon Compounding Pharmacy (TCP) recently issued a voluntary recall of all lots of lyophilized HCG and sermorelin amid FDA concerns about sterility assurance.
So far no complaints have been filed regarding illness or injury stemming from use of the product, but nevertheless a potential lack of sterility may increase the risk of infection and other complications.
The products were distributed between January 18 and July 18 of this year and were for a variety of indications. The specific items affected by the recall are lyophilized HCG in any strength, lyophilized HCG with B12 in any strength, and lyophilized sermorelin of any strength. Consumers and medical professionals should avoid both used and unused bottles. TCP notes that the recall only applies to the specified products – other medications produced by TCP are not a part of the recall.
Individuals who have the items in their possession are encouraged to discontinue use and quarantine unused products. Consumers can also contact TCP to receive further instructions on how to potentially return unused recalled items.
In July 2015 a compounding pharmacy in Washington State recalled semorelin injectables among other compounded products amid similar sterilty concerns. The FDA encourages individuals to report any adverse effects to its MedWatch Adverse Event Reporting program.